Currently, 40% of all NMFC items fall within the scope of review. That represents more than 5,000 potential changes. The final docket for phase one (docket 2025-1) will be released on Jan. 30 with a ...

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating ...

Learn about Ionis Pharmaceuticals' innovative RNA-targeted therapy and their potential for significant revenue growth. Read ...

From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

A Japanese space startup said its second attempt to launch a rocket carrying small satellites into orbit had been terminated ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...

NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study ( NCT06617429 ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial ...

U.S. stocks sank to their second-worst loss of the year after the Federal Reserve signaled it may deliver fewer interest ...

Ahmad Ridhwan Azizan, partner expert at Roland Berger Southeast Asia, and Truong Bui, partner and GM at Roland Berger Vietnam ...

Pending FDA clearance of the IND application, Neurizon said it anticipated Massachusetts General Hospital filing a protocol ...